Sarepta Therapeutics | SRPT - Cash And Equivalent


Sarepta Therapeutics reported $801.28M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amgen USD 9.13B 316M Dec/2025
BioCryst Pharmaceuticals USD 84.08M 3.95M Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Capricor Therapeutics USD 19.51M 3.73M Sep/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Insmed USD 510.44M 175.68M Dec/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Moderna USD 2.6B 1.46B Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novavax USD 268.02M 14.28M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Tectonic Therapeutic USD 268.44M 18.94M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025